Development of Benign Prostatic Hyperplasia (BPH) progression risk calculator

Trial description: Over the last several years, many clinical trials and findings have been published to guide the optimal medical management of men with increased risk of BPH, the wealth and complexity of clinical trial data also make it difficult to establish a personalized treatment strategy. An easily accessible tool, that accounts for individual measurements and provides tangible and treatment-specific risk estimates, will be beneficial to physicians and allow for better informed medical treatment decisions. This study will be conducted to build a predictive model that will estimate the personalized risk of symptom deterioration and acute urinary retention (AUR) or BPH-related surgery in subjects who are at risk of disease progression (i.e. age greater than or equal to 50 years, moderate to severe lower urinary tract symptoms (LUTS), prostate volume (PV) greater than or equal to 30 milliliter (mL) and prostate specific antigen (PSA) greater than or equal to 1.5 nanograms per milliliter (ng/mL), with and without therapeutic intervention (Tamsulosin, Dutasteride or combination treatment). The study will be predictive modeling based on data (re-use) from 10 GlaxoSmithKline (GSK) sponsored phase III and IV Dutasteride clinical trials. All the studies which are considered to be included in this meta-analysis are completed and published and vary in length between 36 weeks to 4 years.